STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions

A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence

Pope Leo wraps up South America tour that tested recovery from cancer surgery

Women's criminal records wiped for abortion offences
